Clinical Trials
Friday, September 21st, 2012
American Heart Association: September 13, 2012 Enrollment in the Stenting and Aggressive Medical Management for Preventing Recurrent stroke in Intracranial Stenosis (SAMMPRIS) trial was halted due to the high risk of stroke or death within 30 days of enrollment in the percutaneous transluminal angioplasty and stenting arm relative to the medical arm. This analysis focuses on […]
Clinical Trials
Friday, September 21st, 2012
American College of Cardiology Foundation: 9/1/12. Objectives The aim of this prospective randomized study was to assess the impact of renal artery denervation in patients with a history of refractory atrial fibrillation (AF) and drug-resistant hypertension who were referred for pulmonary vein isolation (PVI). Background Hypertension is the most common cardiovascular condition responsible for the development and maintenance […]
Clinical Trials
Sunday, September 16th, 2012
Circep.ahajournals.org: 9/12/12 isolation of the pulmonary veins and posterior left atrium with a single ring of radiofrequency lesions (SRI) may result in fewer atrial fibrillation (AF) recurrences than wide antral pulmonary vein isolation (WAI) by abolishing extravenous AF triggers. The effect of mitral isthmus line (MIL) ablation on outcomes after SRI has not previously been assessed. […]
Clinical Trials
Sunday, September 16th, 2012
Jnis.bmj.com: 9/12/12 To investigate the relationship between physician and site experience and the risk of 30 day hemorrhagic and ischemic strokes in the stenting arm of the Stenting and Aggressive Medical Management for the Prevention of Recurrent Ischemic Stroke (SAMMPRIS) trial. Methods Study records and an investigator survey were examined for physician and site related factors, including: […]
Clinical Trials
Sunday, September 16th, 2012
Stroke.ahajournals.org: September 11, 2012 ResolutionMD mobile application runs on a Smartphone and affords vascular neurologists access to radiological images of patients with stroke from remote sites in the context of a telemedicine evaluation. Although reliability studies using this technology have been conducted in a controlled environment, this study is the first to incorporate it into a […]
Clinical Trials
Sunday, September 16th, 2012
Nejm.org: September 6, 2012 The tumult arising from revelations of serious safety risks associated with widely prescribed drugs, including rosiglitazone (Avandia, GlaxoSmithKline), rofecoxib (Vioxx, Merck), and celecoxib (Celebrex, Pfizer), has led to widespread recognition that improvement is needed in our national system of ensuring drug safety. Notwithstanding federal legislation in 2007 that strengthened the authority of […]
Clinical Trials
Sunday, September 16th, 2012
Jama.jamanetwork.com: 9/6/12 Marc A. Rodwin, JD, PhD; John D. Abramson, MD, MS Knowledge of the benefits and risks of prescription drugs is based mainly on published reports of clinical trials, yet the medical literature may present an incomplete and potentially biased sample of clinical trials.1 Trials with positive results generally are published more frequently than studies that […]
Clinical Trials
Friday, September 7th, 2012
Onlinelibrary.wiley.com: 8/24/12 Study Objective To evaluate the impact of a pharmacist-led warfarin patient self-management program on quality of life and anticoagulation control compared with management in a physician-led specialized anticoagulation clinic. Design Prospective, randomized, controlled, open-label trial. Setting Tertiary care academic medical center. Patients A total of 114 patients aged 18–75 years who were followed at […]
Clinical Trials
Friday, August 31st, 2012
NIH study also shows that overall stroke risk is down from 10 years ago Nih.gov: Wednesday, August 29, 2012 Aspirin combined with the antiplatelet drug clopidogrel is no better than aspirin alone for stroke prevention in people with a history of lacunar strokes, and the combination carries a greater risk of gastrointestinal bleeding, according to results […]
Clinical Trials
Friday, August 31st, 2012
By Thomas H. Maugh II Los Angeles Times August 28, 2012, 11:29 a.m. Since tissue plasminogen activator (tPA) was approved by the Food and Drug Administration in 1996 for the dissolution of blood clots in the brain that cause strokes, it has been the primary treatment for stroke victims. But it has several limitations. In most […]
